According to a report in China Daily on February 5, 2026
BEIJING — China is pushing forward the clinical adoption of brain-computer interface (BCI) technology, aiming to provide new treatment pathways for millions of children with attention deficit hyperactivity disorder (ADHD) and other neuropsychiatric conditions.
On Jan. 31, Zhejiang Qiangnao Technology Co Ltd (BrainCo) launched its “FocusXin” Medical Edition, a BCI-based device designed for pediatric ADHD intervention, at the Brain-Computer Interface Diagnosis and Treatment Innovation Exchange in Beijing. The product integrates both software and hardware, marking a global first in fully certified medical device use for children’s attention training.
BCI systems link brain activity to external devices, allowing for real-time monitoring and intervention. By combining rehabilitation software with a lightweight prefrontal lobe EEG collector, FocusXin simplifies traditional EEG setups, making clinical application more accessible while reducing operational complexity.
Tan Weihong, academician at the Chinese Academy of Sciences, said the initiative represents a new model of “diagnosis-treatment-rehabilitation” integration, emphasizing the potential of BCI to transform pediatric neurorehabilitation. “Our goal is simple: to ensure BCI technologies translate into tangible health benefits for patients,” Tan said.
ADHD affects roughly 6.4 percent of Chinese children aged 6–16, amounting to an estimated 23 million young patients, according to the first nationwide epidemiological survey on child mental health in China. The launch of FocusXin comes as part of broader efforts to explore multidisciplinary solutions for neuropsychiatric disorders.
Experts at the event highlighted the importance of collaboration across hospitals, schools, and technology companies to optimize treatment pathways, cultivate specialized talent, and build a robust application ecosystem. Zhang Guojun, former Party secretary of Beijing Children’s Hospital, noted that emerging technologies like BCI offer novel intervention options for conditions that are difficult to address solely with medication.
Han Bicheng, founder and CEO of BrainCo, said the company aims to enhance the lives of millions of patients with neuropsychiatric disorders over the next decade. “By bridging laboratory research with clinical practice, we hope to scale BCI applications in ways that are safe, effective, and accessible,” Han added.
The introduction of FocusXin Medical Edition demonstrates China’s growing commitment to integrating high-tech solutions into healthcare, signaling opportunities for innovation-driven growth in the global pediatric neurotech sector.
Key Takeaways for International Readers:
FocusXin represents a globally unique combination of software and hardware for ADHD treatment.
China is accelerating BCI clinical translation, targeting both public health impact and technological leadership.
The initiative reflects broader trends in pediatric neurorehabilitation, multidisciplinary collaboration, and commercial medical device innovation.